Teduglutide in amyloidosis-associated intestinal failure

Area of Science:

• Gastroenterology
• Endocrinology
• Oncology

Background:

• Amyloidosis is a complex disease with frequent gastrointestinal (GI) involvement, often causing nonspecific symptoms like weight loss and malabsorption.
• Current therapies for GI amyloidosis focus on symptom management and slowing amyloid deposition, lacking specific treatments.
• Intestinal failure (IF) is a severe complication in some amyloidosis patients, necessitating supportive care like parenteral nutrition.

Observation:

• A case study of an AL-amyloidosis patient with significant GI involvement and IF is presented.
• The patient experienced substantial improvements in quality of life (QoL) and achieved independence from parenteral nutrition during teduglutide treatment.
• Histopathological analysis showed a near-complete resolution of Congo-Red-positive amyloid deposits in the intestine after six months of therapy.

Findings:

• Teduglutide, a glucagon-like peptide-2 (GLP-2) analogue, demonstrated efficacy in treating GI amyloidosis with IF.
• Treatment resulted in improved stool consistency, stabilized urinary output, and enhanced body weight and composition.
• The patient's reliance on parenteral nutrition was eliminated, reducing associated risks and improving overall QoL.

Implications:

• Teduglutide offers a promising therapeutic option for amyloidosis patients suffering from IF and parenteral nutrition dependence.
• This intestinotrophic therapy may help manage GI manifestations of amyloidosis and improve patient outcomes.
• Further research into GLP-2 analogues could expand treatment strategies for refractory GI conditions.